Agilent Technologies Inc (A) Position Boosted by Creative Planning

Share on StockTwits

Creative Planning lifted its holdings in shares of Agilent Technologies Inc (NYSE:A) by 5.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,507 shares of the medical research company’s stock after acquiring an additional 1,025 shares during the quarter. Creative Planning’s holdings in Agilent Technologies were worth $1,248,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Marshall Wace LLP raised its holdings in Agilent Technologies by 170.0% in the third quarter. Marshall Wace LLP now owns 2,649,502 shares of the medical research company’s stock worth $186,896,000 after purchasing an additional 1,668,360 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in Agilent Technologies by 1,375.4% in the third quarter. Point72 Asset Management L.P. now owns 1,504,860 shares of the medical research company’s stock worth $106,153,000 after purchasing an additional 1,402,860 shares in the last quarter. Pendal Group Ltd raised its holdings in Agilent Technologies by 17,076.7% in the fourth quarter. Pendal Group Ltd now owns 1,227,965 shares of the medical research company’s stock worth $71,925,000 after purchasing an additional 1,220,816 shares in the last quarter. OppenheimerFunds Inc. raised its holdings in Agilent Technologies by 12.5% in the third quarter. OppenheimerFunds Inc. now owns 8,590,725 shares of the medical research company’s stock worth $605,989,000 after purchasing an additional 954,104 shares in the last quarter. Finally, American Century Companies Inc. raised its holdings in Agilent Technologies by 16.9% in the third quarter. American Century Companies Inc. now owns 5,359,933 shares of the medical research company’s stock worth $378,090,000 after purchasing an additional 774,771 shares in the last quarter.

In other news, insider Dominique Grau sold 8,902 shares of the firm’s stock in a transaction on Monday, December 3rd. The stock was sold at an average price of $74.00, for a total transaction of $658,748.00. Following the completion of the transaction, the insider now directly owns 103,387 shares in the company, valued at $7,650,638. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Rodney Gonsalves sold 1,500 shares of the firm’s stock in a transaction on Wednesday, November 28th. The shares were sold at an average price of $71.06, for a total value of $106,590.00. The disclosure for this sale can be found here. Insiders have sold 43,816 shares of company stock valued at $3,242,727 over the last 90 days.

Shares of NYSE:A opened at $75.80 on Monday. Agilent Technologies Inc has a 1-year low of $60.42 and a 1-year high of $76.69. The company has a quick ratio of 2.74, a current ratio of 3.29 and a debt-to-equity ratio of 0.39. The firm has a market cap of $24.08 billion, a PE ratio of 27.17, a P/E/G ratio of 2.12 and a beta of 1.33.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Monday, November 19th. The medical research company reported $0.81 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.07. Agilent Technologies had a return on equity of 19.84% and a net margin of 6.43%. The firm had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.26 billion. During the same period last year, the company earned $0.67 earnings per share. The company’s revenue was up 8.8% on a year-over-year basis. On average, sell-side analysts predict that Agilent Technologies Inc will post 3.04 EPS for the current fiscal year.

Agilent Technologies declared that its Board of Directors has authorized a stock repurchase plan on Monday, November 19th that authorizes the company to buyback $1.75 billion in shares. This buyback authorization authorizes the medical research company to repurchase up to 8.8% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.

The business also recently declared a quarterly dividend, which was paid on Wednesday, January 23rd. Stockholders of record on Monday, December 31st were issued a dividend of $0.164 per share. The ex-dividend date of this dividend was Friday, December 28th. This is an increase from Agilent Technologies’s previous quarterly dividend of $0.15. This represents a $0.66 annualized dividend and a dividend yield of 0.87%. Agilent Technologies’s dividend payout ratio (DPR) is presently 23.66%.

A has been the subject of a number of research reports. Needham & Company LLC initiated coverage on Agilent Technologies in a report on Wednesday, January 2nd. They issued a “buy” rating and a $77.00 price objective for the company. Morgan Stanley increased their price objective on Agilent Technologies from $86.00 to $89.00 and gave the stock an “overweight” rating in a report on Tuesday, November 20th. ValuEngine upgraded Agilent Technologies from a “hold” rating to a “buy” rating in a report on Friday, November 2nd. Alembic Global Advisors downgraded Agilent Technologies to a “hold” rating in a report on Monday, December 31st. Finally, Zacks Investment Research downgraded Agilent Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, October 16th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $81.17.

WARNING: “Agilent Technologies Inc (A) Position Boosted by Creative Planning” was originally published by Week Herald and is the property of of Week Herald. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://weekherald.com/2019/02/11/agilent-technologies-inc-a-position-boosted-by-creative-planning.html.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.

Featured Story: How to calculate the annual rate of depreciation

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies Inc (NYSE:A).

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply